Losartan Potassium
Product Images NDC 66116-452

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 66116-452). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem Structure For Losartan Potassium (F88c39fa Ed74 42f4 A886 C268daf8f3a6 01)

Chemical structure of Losartan Potassium showing its molecular arrangement including chlorinated imidazole and tetrazole rings, a hydroxymethyl group, and a potassium ion (K+).*

FDA Label Image

Figure 1 (F88c39fa Ed74 42f4 A886 C268daf8f3a6 02)

A line graph comparing the percentage of patients with a primary endpoint over a 66-month study period for Atenolol and Losartan Potassium. The x-axis represents study months, and the y-axis shows the percentage of patients. The graph highlights an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure 2 (F88c39fa Ed74 42f4 A886 C268daf8f3a6 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period on Atenolol versus Losartan Potassium. The graph shows a lower percentage of events in the Losartan Potassium group, with an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Figure 3 (F88c39fa Ed74 42f4 A886 C268daf8f3a6 04)

A comparative forest plot illustrating hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol across multiple patient subgroups for primary composite and stroke outcomes. The chart presents event rates and hazard ratios for different demographics including age, gender, race, presence of hypertension, diabetes, and cardiovascular disease history, showing favored outcomes based on subgroup analyses.*

FDA Label Image

Figure 4 (F88c39fa Ed74 42f4 A886 C268daf8f3a6 05)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The graph shows two lines, one solid representing Losartan Potassium and one dotted representing placebo, demonstrating a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Losartan Potassium 50mg (F88c39fa Ed74 42f4 A886 C268daf8f3a6 06)

Label for Losartan Potassium Tablets USP 50 mg by MedVantx, Inc. The label indicates a package containing 30 tablets with storage instructions at controlled room temperature (20°-25°C or 68°-77°F). It includes directions to see the package insert for dosage and a notice that the product is sample only, not for sale. Additional text advises keeping the container tightly closed and out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.